S Gastrointestinal And Liver Disease 12th Edition Page

A) Vitamin E 800 IU/day B) Pioglitazone 45 mg/day C) Resmetirom 80 mg/day D) Semaglutide 1.0 mg/week

This edition integrates the latest scientific breakthroughs with practical clinical management across its two volumes: s gastrointestinal and liver disease 12th edition

: Updated sections on the surgical and endoscopic treatment of obesity, reflecting the shift toward minimally invasive interventions. Structure and Educational Features Templated Format A) Vitamin E 800 IU/day B) Pioglitazone 45

A 52-year-old with obesity, T2DM, and ALT 65 U/L undergoes MRI-PDFF showing 18% hepatic fat and F2 fibrosis by MRE. Which of the following is the most appropriate first-line pharmacotherapy according to the 12th edition guidelines? Furthermore, the editors have expanded the section on

12th Edition Sleisenger and Fordtran's Gastrointestinal and Liver Disease released on December 10, 2025

Perhaps the most significant update in the 12th edition is the deepened focus on the gut microbiome. Previous editions introduced the concept; the 12th edition integrates it into the pathogenesis of numerous conditions. The text thoroughly revisits the role of dysbiosis in Inflammatory Bowel Disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome. Furthermore, the editors have expanded the section on environmental risk factors, reflecting current literature on diet, antibiotics, and their long-term impact on gut health.